<DOC>
	<DOC>NCT00622284</DOC>
	<brief_summary>The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (5.0 mg daily) compared to glimepiride given for 104 weeks as add-on therapy to preferably &gt; 1500 mg metformin in patients with type 2 diabetes mellitus with insufficient glycaemic control</brief_summary>
	<brief_title>Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criteria: 1. Male and female patients with a diagnosis of type 2 diabetes mellitus and previously treated with metformin alone or with metformin and one other oral antidiabetic drug 2. Glycosylated haemoglobin (HbA1c) 6.0 9.0% at screening for patients treated with metformin and one other oral antidiabetic drug 3. HbA1c 6.5 10.0% at screening for patients treated with metformin alone 4. HbA1c 6.5 10.0% at beginning of the placebo runin phase Exclusion criteria: 1. Myocardial infarction, stroke or transient ischemic attack (TIA) 2. Impaired hepatic function 3. Renal failure or renal impairment 4. Treatment with rosiglitazone or pioglitazone within 6 months prior to screening 5. Treatment with insulin or glucagonlike peptide 1 (GLP1) analogue/antagonists within 3 months prior to screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>